Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.890
+0.010 (0.53%)
At close: Mar 9, 2026, 4:00 PM EDT
1.885
-0.005 (-0.26%)
After-hours: Mar 9, 2026, 6:42 PM EDT
Inhibikase Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
258.52M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Coherus Oncology | 277.73M |
| Cellectis | 82.55M |
| Fennec Pharmaceuticals | 38.79M |
| Prelude Therapeutics | 10.50M |
| Ovid Therapeutics | 6.61M |
| Surrozen | 3.60M |
| Orchestra BioMed Holdings | 2.82M |
| Abeona Therapeutics | 400.00K |
IKT News
- 3 months ago - Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 3 months ago - Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 3 months ago - Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension - GlobeNewsWire
- 4 months ago - Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 7 months ago - Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer - GlobeNewsWire
- 7 months ago - Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 10 months ago - Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 11 months ago - Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer - GlobeNewsWire